News

TargED enters clinic with Phase 1 trial of its groundbreaking thrombolytic TGD001

TargED has dosed the first participant with its groundbreaking thrombolytic drug, TGD001. This Phase 1a clinical trial will assess TGD001’s safety and tolerability in healthy volunteers.

ACI worked with TargED in 2024 through the Calling2scale program promoted by EIT.